**Uitdehaag *et al*. (2018) Supplementary Table S1**. Chemical structures and suppliers of compounds used in this study (in order of FDA-approval date)

|  |  |  |  |
| --- | --- | --- | --- |
| **Chemical structure** | **Generic name** | **Research code** | **Supplier** |
|  | copanlisib | BAY 80-6946 | Chemscene |
|  | tivozanib | AV-951 | MedKoo |
|  | neratinib | HKI-272 | LC Laboratories |
|  | ceritinib | L01XE28 | Selleck |
|  | brigatinib | AP26113 | MedChemExpress |
|  | midostaurin | PKC412 | MedChemExpress |
|  | alectinib | CH5424802 | MedKoo |
|  | idelalisib | CAL-101 | LC Laboratories |
|  | acalabrutinib | ACP-196 | MedChemExpress |
|  | abemaciclib | LY2835219 | MedKoo |
|  | ibrutinib | PCI-32765 | MedKoo |
|  | palbociclib | PD-0332991 | LC Laboratories |
|  | osimertinib | AZD-9291 | Selleck |
|  | ribociclib | LEE 011 | LC Laboratories |
|  | lenvatinib | E7080 | Selleck |
|  | cobimetinib | GDC-0973 / XL-518 | Selleck |
|  | nintedanib | BIBF-1120 | LC Laboratories |
|  |  |  |  |
| **Earlier kinase inhibitors used as reference material** | | | |
|  | dabrafenib | GSK2118436 | Selleck |
|  | trametinib | GSK1120212 | LC Laboratories |
|  | erlotinib | OSI-774 | LC Laboratories |
|  | gefitinib | ZD-1839 | LC Laboratories |
|  | lapatinib | GW-2016 | LC Laboratories |
|  | afatinib | BIBW-2992 | LC Laboratories |
|  | crizotinib | PF-02341066 | LC Laboratories |